<DOC>
	<DOCNO>NCT01356823</DOCNO>
	<brief_summary>This phase II clinical study novel recombinant HPV 16/18 bivalent vaccine express E. coli . The primary purpose study evaluate dosage HPV vaccine induce high antibody time cause less adverse event . The secondary purpose study evaluate safety immunopersistence study vaccine .</brief_summary>
	<brief_title>Dose-Ranging Study Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine</brief_title>
	<detailed_description>Totally 1600 healthy woman 18-25 year age enrol . The participant randomly stratify 4 group receive different dosage human papillomavirus ( HPV ) vaccine placebo administer intramuscularly accord 0-1-6 month schedule . The woman actively monitor adverse event 1 month injection . Severe adverse event trial follow . Serum sample subject would collect day 0 , 7m , 24m , 48m 72m evaluate immunogenicity immuno-persistency .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Written inform consent subject prior enrolment ; Female , include , 18 25 year age time enrolment ; Subjects must free obvious health problem ; Not pregnant plan pregnancy ; Pregnant breastfeeding plan pregnancy whole study ( Month 07 ) ; Previous vaccination HPV ; Having severe allergic history immunodeficiency ; Chemotherapy immunosuppressive agent use ;</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Human Papilloma Virus 16</keyword>
	<keyword>Human Papilloma Virus 18</keyword>
	<keyword>vaccine</keyword>
	<keyword>Cervical Intraepithelial Neoplasia</keyword>
	<keyword>cervical Cancer</keyword>
</DOC>